Fresh off first regulatory win, ImmunityBio hints at financial troubles

ImmunityBio has launched a round of layoffs amid potentially troubled financial waters. The staffing cuts come just months after the firm scored FDA approval of its first product, Anktiva (nogapendekin alfa inbakicept-pmln), to be used in combination with Bacillus Calmette-Guérin (BCG) to treat non-muscle invasive bladder cancer (NMIBC).